$5.41
2.35% yesterday
Nasdaq, Oct 02, 10:00 pm CET
ISIN
US1374041093
Symbol
CADL

Candel Therapeutics Inc Stock price

$5.41
-0.45 7.68% 1M
+0.10 1.88% 6M
-3.27 37.67% YTD
-1.40 20.56% 1Y
+2.21 69.06% 3Y
-1.59 22.71% 5Y
-1.59 22.71% 10Y
-1.59 22.71% 20Y
Nasdaq, Closing price Thu, Oct 02 2025
-0.13 2.35%
ISIN
US1374041093
Symbol
CADL
Industry

Key metrics

Basic
Market capitalization
$297.0m
Enterprise Value
$203.9m
Net debt
positive
Cash
$100.7m
Shares outstanding
54.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.3
Financial Health
Equity Ratio
62.1%
Return on Equity
-83.2%
ROCE
-39.7%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-35.1m | $-43.4m
EBIT
$-36.2m | $-44.4m
Net Income
$-22.1m | $-19.8m
Free Cash Flow
$-29.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-1.2% | -34.0%
EBIT
-1.6% | -33.0%
Net Income
55.7% | 64.2%
Free Cash Flow
3.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.4
FCF per Share
$-0.5
Short interest
17.1%
Employees
38
Rev per Employee
$0.0
Show more

Is Candel Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Candel Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Candel Therapeutics Inc forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Candel Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Candel Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
11% 11%
-
- Research and Development Expense 20 20
3% 3%
-
-35 -35
1% 1%
-
- Depreciation and Amortization 1.10 1.10
12% 12%
-
EBIT (Operating Income) EBIT -36 -36
2% 2%
-
Net Profit -22 -22
56% 56%
-

In millions USD.

Don't miss a Thing! We will send you all news about Candel Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Candel Therapeutics Inc Stock News

Positive
Proactive Investors
4 days ago
Candel Therapeutics Inc (NASDAQ:CADL) said Monday that its experimental treatment CAN-2409 significantly extended the time patients lived without their prostate cancer returning, according to results from a large late-stage study presented at the annual meeting of the American Society for Radiation Oncology. The therapy, also known as aglatimagene besadenovec, was tested in 745 men with interme...
Neutral
GlobeNewsWire
4 days ago
NEEDHAM, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, presented subgroup analyses focused on the radiation regimen from the Company's positive phase 3 clinical trial of CAN-2409 (aglatimagene besadeno...
Neutral
GlobeNewsWire
16 days ago
NEEDHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for an oral presentation at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting,...
More Candel Therapeutics Inc News

Company Profile

Candel Therapeutics, Inc. operates as a biopharmaceutical company that develops and commercializes cancer immunotherapy drugs. It offers aglatimagene besadenovec (CAN-2409), a replication-deficient adenovirus that delivers within infected cancer cells the herpes simplex virus thymidine kinase (HSV-tk) gene. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Head office United States
CEO Paul-Peter Tak
Employees 38
Founded 2002
Website www.candeltx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today